Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pieris has released preclinical in-vitro and in-invo data from the study evaluating PRS-080 Anticalin antagonist program targeting hepcidin.
Subscribe to our email newsletter
PRS-080 demonstrated Anticalins’ ability to encapsulate small targets like hepcidin with specificity and potency.
In the trial, PRS-080 displayed sub-nanomolar potency, which translated into cell-based and in-vivo efficacy.
PRS-080 demonstrated complete inhibition of hepcidin-induced hypoferremia in a dose-dependent manner, in a preclinical model of efficacy.
Pieris CEO Stephen Yoder said their hepcidin antagonist program highlights Pieris’ strategy of pursuing therapeutic programs with meaningful, clinically relevant differentiation over conventional molecules.
"We are aiming to achieve first-in-man readiness no later than the beginning of 2013, which girds this program with first-in-class potential," Yoder said.